ENXTPA:ALBIO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally.


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has Biosynex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALBIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-20.8%

ALBIO

-11.5%

FR Medical Equipment

8.7%

FR Market


1 Year Return

197.9%

ALBIO

42.8%

FR Medical Equipment

-2.4%

FR Market

Return vs Industry: ALBIO exceeded the French Medical Equipment industry which returned 47.4% over the past year.

Return vs Market: ALBIO exceeded the French Market which returned -3.8% over the past year.


Shareholder returns

ALBIOIndustryMarket
7 Day-20.8%-11.5%8.7%
30 Day-34.4%-1.9%15.9%
90 Day84.6%35.6%1.3%
1 Year197.9%197.9%42.8%42.8%-0.7%-2.4%
3 Year72.9%72.1%43.9%42.1%11.2%2.2%
5 Year121.3%107.4%144.9%139.2%31.1%14.3%

Price Volatility Vs. Market

How volatile is Biosynex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biosynex undervalued compared to its fair value and its price relative to the market?

68.78x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALBIO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALBIO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALBIO is poor value based on its PE Ratio (68.8x) compared to the Medical Equipment industry average (47.3x).

PE vs Market: ALBIO is poor value based on its PE Ratio (68.8x) compared to the French market (15.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALBIO is good value based on its PB Ratio (2.5x) compared to the FR Medical Equipment industry average (2.6x).


Next Steps

Future Growth

How is Biosynex forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosynex has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Biosynex performed over the past 5 years?

64.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALBIO has a large one-off loss of €255.3K impacting its December 31 2019 financial results.

Growing Profit Margin: ALBIO's current net profit margins (3.2%) are higher than last year (1.7%).


Past Earnings Growth Analysis

Earnings Trend: ALBIO has become profitable over the past 5 years, growing earnings by 64.5% per year.

Accelerating Growth: ALBIO's earnings growth over the past year (105.5%) exceeds its 5-year average (64.5% per year).

Earnings vs Industry: ALBIO earnings growth over the past year (105.5%) exceeded the Medical Equipment industry -1.8%.


Return on Equity

High ROE: ALBIO's Return on Equity (3.7%) is considered low.


Next Steps

Financial Health

How is Biosynex's financial position?


Financial Position Analysis

Short Term Liabilities: ALBIO's short term assets (€15.1M) exceed its short term liabilities (€8.4M).

Long Term Liabilities: ALBIO's short term assets (€15.1M) exceed its long term liabilities (€8.6M).


Debt to Equity History and Analysis

Debt Level: ALBIO's debt to equity ratio (32.8%) is considered satisfactory.

Reducing Debt: ALBIO's debt to equity ratio has reduced from 47.7% to 32.8% over the past 5 years.

Debt Coverage: Insufficient data to determine if ALBIO's debt is well covered by operating cash flow.

Interest Coverage: ALBIO's interest payments on its debt are well covered by EBIT (7.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Biosynex's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALBIO's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

€96k

CEO Compensation


CEO

Thierry Paper

no data

Tenure

€96,000

Compensation

Dr. Thierry Paper is the Founder of Biosynex S.A. and serves as its Managing Director and Director. Dr. Paper served as Chairman and General Manager of Biosynex S.A. 


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Biosynex SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biosynex SA
  • Ticker: ALBIO
  • Exchange: ENXTPA
  • Founded: 1993
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €76.738m
  • Shares outstanding: 9.14m
  • Website: https://www.biosynex.com

Number of Employees


Location

  • Biosynex SA
  • 22 Boulevard Sébastien Brant
  • Illkirch-Graffenstaden
  • Alsace
  • 67400
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALBIOENXTPA (Euronext Paris)YesSocial SharesFREURMar 2011

Biography

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. It offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women’s health, as well as instruments. The company also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper-and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 23:08
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.